首页 › 非小细胞肺癌 › 田纳西州 › Knoxville
Knoxville TN 非小细胞肺癌临床试验
14项针对 非小细胞肺癌的研究正在 Knoxville及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
招募中2/3 期
- Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 277891, Knoxville
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
招募中3 期
- Thompson Cancer Survival Center ( Site 0168), Knoxville
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
招募中3 期
- The University of Tennessee Medical Center ( Site 3223), Knoxville
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
招募中3 期
- Tennessee Cancer Specialists, Knoxville
- Tennessee Cancer Specialists - Parkwest Location, Knoxville
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
招募中3 期
- University of Tennessee Medical Center Knoxville ( Site 0082), Knoxville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Tennessee Cancer Specialists Dowell Springs location, Knoxville
- University of Tennessee Medical Center, Knoxville
- Tennessee Cancer Specialists - Parkwest Location, Knoxville
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Tennessee Cancer Specialists, Knoxville
- University of Tennessee, Knoxville
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- University of Tennessee Medical Center, Knoxville
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
招募中2 期
- University of Tennessee Medical Center, Knoxville
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
招募中3 期
- University of Tennessee Medical Center, Knoxville
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
招募中1/2 期
- University of Tennessee Medical Center, Knoxville
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
招募中2/3 期
- University of Tennessee Medical Center, Knoxville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- University of Tennessee Medical Center, Knoxville
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
招募中2 期
- University of Tennessee Medical Center, Knoxville
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
Knoxville的其他研究
- 肥胖症10 项研究
- 肺癌10 项研究
- 乳腺癌9 项研究
- 癌症（所有类型）8 项研究
- 超重7 项研究
- 心力衰竭7 项研究
- 转移性癌症7 项研究
- 心血管疾病6 项研究
- 黑色素瘤5 项研究
- 2型糖尿病5 项研究
- 高血压5 项研究
- 慢性阻塞性肺病5 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。